Spinocerebellar ataxia type 1 (SCA1) is an inherited neurodegenerative disease involving progressive loss of motor and cognitive function resulting from the death of cerebellar neurons. Watase et al.

The Oxford-Harrington Rare Disease Centre ('OHC') today announced the recipients of the 2025 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice.

Director Gregory Bailey reported purchasing 400,000 common shares of Biohaven Ltd. (NYSE:BHVN) on November 13, 2025. The shares were acquired at a price of $7.50, for a total transaction value of ...

Biohaven (EXCHANGE:BHVN) Chief Executive Officer Vlad Coric acquired 666,666 common shares in two transactions on November 13, 2025, at a price of $7.50 per share, for a total value of $4,999,995. The ...

Ten scientists selected for second annual award to pursue innovations in gene, RNA, small molecule and cell therapies to treat rare and ultra-rare diseases OXFORD, England ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $26 from $54 and keeps an Overweight rating on the shares. After the company received a Complete Response Letter from the FDA ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU. Skyclarys ...